Mayne Pharma Expands US Pharmacy to 2.5M Prescriptions After 73% Volume Surge
Adelaide Apothecary is expanding — and demand is driving it
Mayne Pharma Group Limited (ASX: MYX) has announced a major Mayne Pharma Adelaide Apothecary expansion, relocating and scaling its specialty pharmacy fulfilment operations to a new, larger facility in Lexington, Kentucky. The move is a direct response to surging prescription volumes following the March 2026 launch of DistributeRx, which drove a 73% increase in prescriptions relative to pre-launch volumes in February, significantly exceeding management expectations.
The expansion is explicitly demand-led. Rather than a speculative capacity build-out, the investment follows demonstrated volume growth and is designed to sustain that momentum at scale. Across two planned phases, the new facility is targeting annual capacity of over 2.5 million prescriptions (one shift, five days a week), representing an approximately seven-fold increase from the current facility. Operations are expected to commence in early 2027.
When big ASX news breaks, our subscribers know first
What the expansion looks like — and what it costs
A phased, modular build designed for scale
Adelaide Apothecary has secured a new lease over a Lexington, Kentucky premises representing approximately four times the area of its current facility. The fit-out is structured around a scalable, modular automation plan, purpose-built to support high-volume, automated specialty pharmacy fulfilment.
Importantly, the two-phase capacity target assumes a single shift. Should demand warrant it, a second shift can be added beyond Phase 1 and Phase 2, providing built-in upside without requiring additional infrastructure investment. At maximum automation build-out, the facility is positioned to support a monthly prescription volume that management describes as a transformational step-change relative to current throughput.
The end-state positions Adelaide Apothecary as one of the few high-volume independent specialty pharmacies serving the Dermatology and Women’s Health categories in the US — a strategically differentiated footprint in an underserved niche.
Capital investment breakdown
The total investment across both phases is expected to reach up to approximately US$4 million. The table below details the phased structure:
| Phase | Scope | Investment | Status |
|---|---|---|---|
| Phase 1 | Initial manufacturing equipment and facility fit-out | Approx. US$0.2M initial outlay; up to US$2M total | Announced |
| Phase 2 | Automated conveyance and fulfilment infrastructure | Up to US$2M additional capex | Planned |
| Total | Full two-phase build-out | Up to approx. US$4M | Subject to demand |
The US$0.2M figure represents the initial equipment outlay for Phase 1 only. The full Phase 1 commitment is up to US$2M, with Phase 2 representing a further US$2M in automated conveyance and fulfilment infrastructure.
Understanding the disintermediation strategy — and why it matters
What is disintermediation in specialty pharmacy?
Traditional US specialty pharmacy distribution involves multiple intermediaries — wholesalers, pharmacy benefit managers, and specialty distributors — each adding cost and operational friction between the manufacturer and the patient. This layered system increases complexity and typically compresses net sales realisations for pharmaceutical companies.
Mayne Pharma’s strategy is designed to bypass this structure. DistributeRx connects prescribers and patients directly to Adelaide Apothecary, which fulfils prescriptions on a cash-pay basis. By owning the dispensing infrastructure, Mayne Pharma removes the cost and complexity of the traditional model, improving net sales per prescription and giving the company greater control over pricing and margins.
Adelaide Apothecary serves as the licensed pharmacy arm within this model, operating as a fully licensed mail-order and specialty pharmacy across all 50 US states and the District of Columbia. The result is a vertically integrated, direct-to-patient fulfilment channel that is uncommon among listed life sciences companies.
The market opportunity backing this move
The structural tailwind supporting the expansion is substantial. According to Precedence Research, as cited in the announcement, the global ePharmacy market was estimated at US$114 billion in 2025 and is forecast to grow to US$252 billion by 2030, representing a compound annual growth rate (CAGR) of 17%. This growth is driven by rising consumer adoption of digital pharmacy services and home delivery.
Mayne Pharma is targeting the Dermatology and Women’s Health verticals specifically, categories where the company already holds a commercial presence in the US. The expansion aligns Adelaide Apothecary’s capacity with the scale of the addressable opportunity in these segments.
The next major ASX story will hit our subscribers first
Management conviction in the opportunity ahead
Daniel Moore, President, DistributeRx
“Adelaide Apothecary’s expansion unlocks the full potential of what DistributeRx was designed to do, which is to connect patients and prescribers directly to a best-in-class dispensing facility without the cost and complexity of the traditional specialty pharmacy model. The additional capacity and automation will allow us to serve significantly more patients in a more rapid and convenient manner, which is exactly what prescribers and patients are demanding in light of the complexities of the US Healthcare system generally. In turn, we expect to increase the number and rate of referrer prescriptions coupled with higher patient compliance and repeat ordering behaviour that is beneficial to our scale and margins over time.”
Aaron Gray, CEO, Mayne Pharma
“The expansion of Adelaide Apothecary is a direct expression of our confidence in the Mayne Pharma disintermediation strategy led by DistributeRx and our commitment to significantly reduce friction that exists for patients across the pharmacy distribution and reimbursement system in the US. By investing in our own dispensing infrastructure, we are building a durable commercial asset that improves patient access, improves our net sales, and gives Mayne Pharma a structural advantage that elevates as DistributeRx prescription volumes grow. Simplifying the distribution channel via our own cash-based pharmacy is a competitive advantage that very few life sciences companies have and this expansion is our commitment to leveraging the opportunity ahead.”
For investors, the key forward-looking considerations from this announcement include:
- Early 2027 is the targeted commencement date for operations at the new facility.
- Annual prescription capacity is targeted at over 2.5 million at one shift, with a second shift available if demand warrants further expansion.
- Higher patient compliance and repeat ordering behaviour is expected to improve margins over time as volume scales.
- Management has explicitly positioned Adelaide Apothecary as a “durable commercial asset” and strategic differentiator, not merely an operational support function.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to make sure you never miss the next big move.